Mid career · publishing since 2004
Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and TreatmentsSystemic Sclerosis and Related DiseasesChronic Obstructive Pulmonary Disease (COPD) ResearchLung Cancer Treatments and Mutations
Publications
43
Citations
82
Est. group size
—
Recurring co-author estimate
Active years
21
Publishing since 2004
In context
Among 4,491 mid career Medicine PIs within our index
Citations: 82p25 240 · p75 1,552 · cohort median 614
Publications / year (recent): 2.0p25 1.8 · p75 7.2 · cohort median 3.4
Typically publishes in teams of ~10 · 0% small-team papers (≤3 authors) · across 6 venues
Publication cadence
Publications per year over the last 10 years — averaging 2.0/year recently
Collaborators per year
Distinct co-authors at University of Michigan each year — a rough indication of whether the group around this researcher has been growing or contracting. An estimate from co-authorship, not a roster: collaborators are not necessarily lab members, and recent years can be under-counted while indexing catches up.
Recent publications
- Using Imaging to Predict, Identify, and Monitor Progression of Interstitial Lung Disease: Consensus Findings From a Modified Delphi Study
2024
- Effet du nintedanib sur le déclin de la capacité vitale forcée (CVF) chez des patients présentant un syndrome d’emphysème et de fibrose pulmonaire combinés : données de l’essai INBUILD
Revue des Maladies Respiratoires Actualités · 2024
- Effect of Nintedanib on Decline in Forced Vital Capacity (FVC) in Patients With Combined Pulmonary Fibrosis and Emphysema: Data From the INBUILD Trial
2023
- Factors Associated With Persistence With Antifibrotic Therapy in Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Pulmonary Fibrosis Foundation Patient Registry
2023
- Effect of nintedanib on decline in forced vital capacity (FVC) in patients with progressive fibrosing interstitial lung diseases (ILDs) by time since diagnosis*
Pneumologie · 2022
- Acute Exacerbations in Patients with Progressive Fibrosing Interstitial Lung Diseases: Data from the INBUILD Trial
2022
- Changes in Radiological Features in Patients with Progressive Fibrosing ILDs Treated with Nintedanib: A Sub-Study of The INBUILD Trial
2022
- Effect of Nintedanib on Decline in Forced Vital Capacity (FVC) in Patients with Progressive Fibrosing Interstitial Lung Diseases (ILDs) by Time Since Diagnosis
2021
- Understanding the Decision-Making Process of the Multidisciplinary Approach for the Diagnosis of Interstitial Lung Disease: A Qualitative Study
2021
- Effet du nintédanib sur le déclin de la capacité vitale forcée (CVF) chez les patients atteints de pneumopathies interstitielles diffuses (PID) chroniques fibrosantes progressives en fonction du délai écoulé depuis le diagnostic de PID
Revue des Maladies Respiratoires Actualités · 2021
- Effet du nintédanib sur la progression de la pneumopathie interstitielle diffuse (PID) chez des patients atteints d’une PID associée à une maladie auto-immune : données complémentaires de l’étude INBUILD
Revue du Rhumatisme · 2020
- The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Instititial Lung Diseases: Subgroup with Autoimmune Diseases*
Pneumologie · 2020
- Nintedanib in patients with chronic fibrosing Interstitial lung diseases with progressive phenotype: the INBUILD trial*
Pneumologie · 2020
- Time to Diagnosis of Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry
2020
- Nintédanib chez les patients atteints de pneumopathie interstitielle diffuse (PID) chroniques avec un phénotype de fibrose progressive : essai INBUILD
Revue des Maladies Respiratoires Actualités · 2020
Publishes in
- Pneumologie×9
- Revue des Maladies Respiratoires Actualités×3
- Thorax×1
- Revue des Maladies Respiratoires×1
- QJM×1
Similar researchers
By research-topic overlap
- Kevin R. Flaherty
Medicine · University of Michigan
- Justin M. Oldham
Medicine · University of Michigan
- J. Oldham
Medicine · University of Michigan
- Jamie Sheth
Medicine · University of Michigan
- Mauricio Rojas
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile